Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shubi Shahida

Internal Medicine Smithfield, NC Medical Doctor

NPI 1407803562 CMS profile 1200231

712 Wilkins St, Smithfield, NC 27577

Open in the dashboard

General payments

$12,458

870 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shubi Shahida of Smithfield, NC is reported in the CMS Open Payments database as having received $12,458 across 870 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,098 123
2024 General $2,372 133
2023 General $2,171 181
2022 General $1,784 136
2021 General $1,726 121
2020 General $863 68
2019 General $1,445 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shubi Shahida
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Shubi Shahida were reported at $2,098. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Shubi Shahida Internal Medicine median Middle half National median
2019 $1,445 $159 $48–$570 $163
2020 $863 $119 $33–$402 $114
2021 $1,726 $135 $37–$521 $132
2022 $1,784 $141 $42–$496 $149
2023 $2,171 $149 $45–$519 $160
2024 $2,372 $154 $47–$537 $164
2025 $2,098 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,832 153 payments
  2. AstraZeneca Pharmaceuticals LP $1,789 82 payments
  3. GlaxoSmithKline, LLC. $1,014 81 payments
  4. Merck Sharp & Dohme Corporation $858 56 payments
  5. AbbVie, Inc. $830 86 payments
  6. Amgen Inc. $674 57 payments
  7. Kowa Pharmaceuticals America, Inc. $649 63 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $482 32 payments
  9. Lilly USA, LLC $447 29 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $329 20 payments
  11. Other $3,554 211 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,243 867 payments
  2. Education $215 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $943 78 payments
  2. TRELEGY ELLIPTA $844 69 payments
  3. VERQUVO $830 51 payments
  4. RYBELSUS $786 64 payments
  5. FARXIGA $741 31 payments
  6. AIRSUPRA $644 24 payments
  7. Wegovy $589 51 payments
  8. Livalo $535 47 payments
  9. Otezla $513 46 payments
  10. BELSOMRA $406 28 payments
  11. Other $10,123 716 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 278 drugs

Part D claims

26,606

Median for Internal Medicine: 777

Drug cost

$2,372,860

Median for Internal Medicine: $73,373

Branded share of claims

23.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 260 $204,702
Ozempic Semaglutide Brand 169 $203,858
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 260 $197,196
Jardiance Empagliflozin Brand 220 $181,609
Mounjaro Tirzepatide Brand 111 $154,841
Januvia Sitagliptin Phosphate Brand 83 $79,568
Rybelsus Semaglutide Brand 63 $78,525
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 64 $72,194
Linzess Linaclotide Brand 91 $64,672
Tresiba Flextouch U-200 Insulin Degludec Brand 40 $58,066

The 10 drugs with the highest cost, of 278 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$193,361

Of which drugs: $646

Medicare patients

380

Average age 76

Services billed

4,626

258 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 39%
Heart failure 27%
COPD 24%
Osteoporosis 24%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 50 56 $257
Injection, ketorolac tromethamine, per 15 mg J1885 Office 64 357 $162
Injection, ceftriaxone sodium, per 250 mg J0696 Office 63 350 $121
Injection, methylprednisolone acetate, 80 mg J1040 Office 13 14 $100

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$223 — —
TRELEGY ELLIPTA
$197 260 —
Kerendia
$177 67 —
VERQUVO
$145 — —
Otezla
$114 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

870 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record